FollowFilings The Ledger · @followfilings · data: SEC Form 4 ← All receipts

$AGMB

AgomAb Therapeutics NV
$8.81 -40.1% vs prior close

What they do: Biological Products, (No Diagnostic Substances) · Exchange: Nasdaq · Employees: 62

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium. (via Yahoo Finance)

Annual financials (via Yahoo Finance)

YearRevenueEarnings
2024—-$46.3M
2025—-$62.5M

Institutional ownership (via Yahoo Finance, 13F-derived)

Insiders hold: 5.95% · Institutions hold: 53.72% across 37 filers

InstitutionSharesValue% held
Eqt Fund Management S.a R.l.5,141,992$45.3M10.44%
Sanofi2,783,096$24.5M5.65%
Redmile Group, LLC2,733,926$24.1M5.55%
Cormorant Asset Management, LP2,465,348$21.7M5.01%
TCG Crossover Management, LLC2,053,233$18.1M4.17%
Federated Hermes, Inc.1,618,000$14.3M3.29%
Nantahala Capital Management, LLC1,568,188$13.8M3.18%
Casdin Capital, LLC1,550,000$13.7M3.15%

Charts (2)

$AGMB chart
auto
$AGMB chart
2026-10-08 11:00

Insider activity — every transaction, real date, real price

Trade dateFiledNameRoleActionSharesPriceValueStock since
2026-10-082026-10-09Epstein David RDirectorBOUGHT5,000$8.90$44K-4.4%
2026-10-062026-10-07Epstein David RDirectorBOUGHT5,000$8.70$44K-0.3%
2026-10-062026-10-07Kemula Pierre Thadee VictorChief Financial OfficerBOUGHT2,000$8.54$17K-0.3%
2026-10-062026-10-07Kemula Pierre Thadee VictorChief Financial OfficerBOUGHT3,000$8.67$26K-0.3%
2026-10-062026-10-07Kemula Pierre Thadee VictorChief Financial OfficerBOUGHT5,000$8.57$43K-0.3%
2026-10-062026-10-07Knotnerus Tim JasperChief Executive OfficerBOUGHT5,000$8.70$44K-0.3%
2026-10-052026-10-07Epstein David RDirectorBOUGHT5,000$8.57$43K+1.4%
2026-10-052026-10-07Knotnerus Tim JasperChief Executive OfficerBOUGHT6,000$8.48$51K+1.4%

Our calls

PostedTweetPrice at postNowSince post
2026-10-08 11:00A "cluster buy" is several insiders at one company buying the same day. Rare, be$8.68$8.81+1.6%